Trial Profile

Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQB2223 Injection Combined With Penpulimab Injection in Subjects With Advanced Cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Penpulimab (Primary) ; TQB 2223 (Primary)
Indications Cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

10 Dec 2024 Results(As of June 20, 2024, n=21 patients) reporting primary analysis of TQB2223 in combination with penpulimab in patients with relapsed or refractory (RR) lymphoma, presented at the 66th American Society of Hematology Annual Meeting and Exposition
27 Jun 2023 Kept brooder term as indication as per official title, please update further when more indications are added.
14 Jun 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com